Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02572713 · ClinicalTrials.gov registry record
Systemic Synuclein Sampling Study (S4)
A clinical trial, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Completed
- Registry status
- 80
- Enrollment target
NCT02572713 is a clinical trial that has completed, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 80 participants.
The verdict
NCT02572713 has completed, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to measure alpha-synuclein in peripheral body tissues and fluids in Parkinson's disease (PD). This may help in developing better treatments for PD patients in the future.
Interventions
- PROCEDURE Biofluid samplings
- PROCEDURE Tissue samplings
- DRUG DaTSCAN™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02572713
The ClinicalTrials.gov registry entry for NCT02572713 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael J. Fox Foundation for Parkinson's Research, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Biofluid samplings is the first listed.
NCT02572713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02572713 about?
NCT02572713 is a clinical study titled "Systemic Synuclein Sampling Study (S4)". The purpose of this study is to measure alpha-synuclein in peripheral body tissues and fluids in Parkinson's disease (PD). This may help in developing better treatments for PD patients in the future.
What is the current status of trial NCT02572713?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2015-10. Estimated completion is 2017-08-01.
What interventions are being tested in trial NCT02572713?
The interventions under investigation include: Biofluid samplings (PROCEDURE), Tissue samplings (PROCEDURE), DaTSCAN™ (DRUG).
Who is sponsoring clinical trial NCT02572713?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.